166 related articles for article (PubMed ID: 28153500)
1. Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Moody TW; Ramos-Alvarez I; Moreno P; Mantey SA; Ridnour L; Wink D; Jensen RT
Peptides; 2017 Apr; 90():90-99. PubMed ID: 28153500
[TBL] [Abstract][Full Text] [Related]
2. Neurotensin receptors regulate transactivation of the EGFR and HER2 in a reactive oxygen species-dependent manner.
Moody TW; Lee L; Ramos-Alvarez I; Jensen RT
Eur J Pharmacol; 2019 Dec; 865():172735. PubMed ID: 31614143
[TBL] [Abstract][Full Text] [Related]
3. PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.
Moody TW; Lee L; Iordanskaia T; Ramos-Alvarez I; Moreno P; Boudreau HE; Leto TL; Jensen RT
Peptides; 2019 Oct; 120():170017. PubMed ID: 30273693
[TBL] [Abstract][Full Text] [Related]
4. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
5. Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Moody TW; Berna MJ; Mantey S; Sancho V; Ridnour L; Wink DA; Chan D; Giaccone G; Jensen RT
Eur J Pharmacol; 2010 Jul; 637(1-3):38-45. PubMed ID: 20388507
[TBL] [Abstract][Full Text] [Related]
6. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells.
Moody TW; Osefo N; Nuche-Berenguer B; Ridnour L; Wink D; Jensen RT
J Pharmacol Exp Ther; 2012 Jun; 341(3):873-81. PubMed ID: 22389426
[TBL] [Abstract][Full Text] [Related]
7. CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Moody TW; Nuche-Berenguer B; Moreno P; Jensen RT
J Mol Neurosci; 2015 Jul; 56(3):663-72. PubMed ID: 25761747
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Song JY; Kim CS; Lee JH; Jang SJ; Lee SW; Hwang JJ; Lim C; Lee G; Seo J; Cho SY; Choi J
Invest New Drugs; 2013 Dec; 31(6):1458-65. PubMed ID: 24068620
[TBL] [Abstract][Full Text] [Related]
10. Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.
Moody TW; Sancho V; di Florio A; Nuche-Berenguer B; Mantey S; Jensen RT
Peptides; 2011 Aug; 32(8):1677-84. PubMed ID: 21712056
[TBL] [Abstract][Full Text] [Related]
11. Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Misumi K; Sun J; Kinomura A; Miyata Y; Okada M; Tashiro S
Cancer Sci; 2016 Apr; 107(4):444-51. PubMed ID: 26825989
[TBL] [Abstract][Full Text] [Related]
12. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
14. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
15. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
Moody TW; Lee L; Jensen RT
J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
[TBL] [Abstract][Full Text] [Related]
16. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
[TBL] [Abstract][Full Text] [Related]
17. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
19. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.
Moody TW; Ramos-Alvarez I; Jensen RT
Peptides; 2022 Oct; 156():170858. PubMed ID: 35932909
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
